 "Aurobindo Pharma rises on USFDA nod for osteoporosis drug")
Shares of Aurobindo Pharma are trading higher by 2% to Rs 770 on the Bombay Stock Exchange (BSE) after the drug maker received approval from the US Food and Drug Administration (USFDA) to manufacture and market Raloxifene Hydrochloride tablets USP 60 mg.
Raloxifene Hydrochloride tablets are indicated for treatment and prevention of osteoporosis in postmenopausal women.
The product has an estimated market size of US$404 Million for the twelve months ending June 2015, according to IMS.
The product has an estimated market size of US$404 Million for the twelve months ending June 2015, according to IMS.
The stock opened at Rs 774.50 and touched a high of Rs 780 on the BSE. A total of 71,548 shares changed hands on the BSE so far.